Skip to Content
Search
Search
ABOUT BIORASI
LEADERSHIP & SCIENTIFIC ADVISORS
WHY BIORASI
PARTNERSHIP
TESTIMONIALS
THERAPEUTIC EXPERIENCE
DERMATOLOGY
ONCOLOGY
NEPHROLOGY
NEUROLOGY
CELL THERAPY
FOCUSED SOLUTIONS
RESCUE & RECOVERY
DATA SCIENCES
QUALITY
FEASIBILITY
SAFETY & PHARMACOVIGILANCE
CLINICAL MONITORING
PODCAST
RESOURCE LIBRARY
CONTACT US
ABOUT BIORASI
LEADERSHIP & SCIENTIFIC ADVISORS
WHY BIORASI
PARTNERSHIP
TESTIMONIALS
THERAPEUTIC EXPERIENCE
DERMATOLOGY
ONCOLOGY
NEPHROLOGY
NEUROLOGY
CELL THERAPY
FOCUSED SOLUTIONS
RESCUE & RECOVERY
DATA SCIENCES
QUALITY
FEASIBILITY
SAFETY & PHARMACOVIGILANCE
CLINICAL MONITORING
PODCAST
RESOURCE LIBRARY
CONTACT US
Resource • White Paper
Optimizing the Amount of Investigational Materials in ANDA Studies – Part Two
July 12th, 2017
|
ANDA
|
White Paper
For Dermal Semisolid Clinical Studies White Paper Series
Download White Paper
Get Access to this White Paper Now
Share this Story
Related Resources
White Paper
Spotlight on India: Regulatory Enhancements, Modernization, and Robust Data Collection Define India as a Potential Clinical Trial Hub
White Paper
Patient Diversity in Clinical Research: Identifying Challenges, Opportunities, and Best Practices
View All